AD (Alzheimer? S disease): Irreversible neural degradation. The mental function of a patient may be impaired due to the deterioration of Brain problems.
Adni: neural imaging program for Alzheimer's disease
The overall goal of adni is to validate the biological markers used in clinical trials for Alzheimer's disease
Study Design
This study supports the development and research of treatment programmes for slowing down and stopping deteriorating processes of AD. The final goal is to confirm the biological indicators (biological markers) used in the clinical treatment of Alzheimer's Disease)
Knowledge gained by studying data from various forms of adni profile and vertical data:
- The ad pathology has already appeared when people have a normal appearance and no memory loss, and these normal people may already have a slight brain atrophy.
- Typical Pattern of starch-like protein deposition, impaired glucose metabolism, and brain structure change in AD
- Cognitive Decline is more closely related to Tau and then? Deposition
- Ad is characterized by the gradual destruction of the brain connection body. With the development of disease, there are fewer and fewer connections between important areas of the brain.
- In addition to apoE4, many genes are the basis of AD. Adni data has helped identify or confirm 10 of the approximately 20 genes that have been identified
- Cerebrovascular Diseases can accelerate the development of AD
- Both the normal cognitive group and the MCI group are heterogeneous in pathology. Some people do not show signs of AD, some show signs of rapid development of AD, and some show signs of moving towards dementia rather than ad
Background and Basic Principles
Ad is the most common cause of dementia in people over 65 years old, but there is still no way to prevent it. The goal of adni research is to track Disease Progression using biological markers and clinical measurements to assess the structure and function of the brain in four disease states.
Adni participants span four stages: 1/go/2/3
CN normal aging/normal cognition-control subjects
SMC important memory concern-solving the gap between healthy elderly control group and MCI
The cognitive ability score of SMC participants is within the normal range.
Mild Cognitive Impairment
- Early cognitive impairment of emci adni go/2
- MCI Mild Cognitive Impairment adni1/3
- Lmci advanced cognitive impairment adni go/2
Biological Markers
Biological Markers are the substances, measurements, or indicators of biological states. Biomarkers may exist before clinical symptoms occur. Adni uses various biological markers to help predict the onset of Alzheimer's Disease
Study objectives
Adni1:
- Develop improved methods to develop unified standards for obtaining longitudinal, multi-site MRI and PET data for Alzheimer's disease (AD), mild cognitive impairment (MCI), and elderly control patients
- Obtain generally accessible data warehouses, describe longitudinal changes in brain structure and metabolism, and clinical/cognitive and biological marker data to verify imaging substitutes
- In trials involving these patients, develop methods to determine the maximum Therapeutic Effect
- Test A series of hypotheses based on clinical and biological tag data
Andi go:
- Define and describe the ad spectrum phase prior to MCI by recruiting 200 patients with the most mild AD symptoms (emci)
- F18 starch-like protein imaging was performed on CN and lmci subjects of adni1 and newly enrolled emci subjects. Fdpet will be associated with F18 starch-like protein Imaging
- Establish a national F18 starch-like protein Imaging Network, hypothesis for testing the prevalence and severity of brain starch-like Protein Accumulation and Its Relationship with changes in clinical status, MRI, fd-pet, CSF, and adni1 plasma markers
- 3 t mri of all newly enrolled subjects was collected at baseline, 3rd months, 6th months and 12th months
- Longitudinal clinical/cognitive and 500 t mri studies were performed on approximately 1.5 lmci and normal cognitive subjects from adni1 for 2 years
- Collection and analysis of blood and cerebrospinal fluid markers for all newly enrolled emci and follow-up subjects
- Blood samples were collected for DNA and RNA extraction. The newly enrolled subjects will also collect cell-finalized and apocode-type samples
Adc0:
- With the development of pathology, the relationship between clinical, imaging, genetic, and biochemical markers of Alzheimer's disease (AD) is determined.
- Provides information for the neuroscience of AD, identifies diagnostic and prognosis markers and outcome measurements that can be used in clinical trials, and helps develop the most effective clinical trial protocol
- Develop unified standards to obtain longitudinal multi-site MRI and PET data for AD, MCI, and elderly control patients
- Longitudinal clinical, cognitive, MRI, PET (18f-florbetapir and GAF) and blood and cerebrospinal fluid markers were studied for 550 newly enrolled subjects, about 700 subjects of adni1 and adni continued the study for five years.
- Blood samples were collected for DNA and RNA extraction. The newly enrolled subjects will also collect cell-finalized and apocode-type samples
- Verification of clinical diagnostics, imaging, and biological marker substitutes by participation in Neuropathological examinations of adni1, adni go, And adn22.
Adni3:
- Longitudinal changes in cognition and Related Biological Markers
- Prediction of cognitive decline
- Validate the baseline and longitudinal acquisition of biometric markers by associating the results with standard clinical measurements and pathology
- Determine optimal outcome measures for attention to cognitive decline and AV-1451 PET (Tau PET), predictive factors for cognitive decline, normal cognitive participants (level 2 pre-clinical ad trials) inclusion/exclusion criteria for clinical trials of patients with early dementia caused by AD and those with AD (precursor symptom ad test)
- Identifies other known disease proteins found in the AD brain and genes, as well as the role of newly discovered genes, proteins, and analytics, which provide useful information on ad onset/diagnosis
Study Design of adni
